5201W-11 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Ad

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study)

Type of Study
Neuroscience - Brain Tumor
Short Description

To confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

Status
Open
Principal Investigator
John Henson, MD
Eligibility Notes
  • Patients with histologically confirmed, newly diagnosed, de novo glioblastoma.
  • Surgical resection followed by conventional chemoradiation with temozolomide attempted.
  • No history, presence, or suspicion of metastatic disease.
  • No additional treatment for glioblastoma, aside from surgical resection and chemoradiation with temozolomide.
Contact Name
Nathan Hansen and Becky Wood
Phone
206-320-3542
Alternate Phone
206-320-7115
Email
nathan.hansen@swedish.org
Alternate Email
becky.wood@swedish.org